|S.No.||Company Name||Short Description||No of Drugs||Company Drug Price||Action|
|1||Bristol-Myers Squibb||Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.||6||75.00||BUY||Your Query|
|S.No.||Updated On||Drug||Price in USD||Action|
|1||Jun, 2020||Baraclude Drug Sales & Forecast|
BMS drug Baraclude was first approved in March 2005 and subsequent approvals in Japan and the five major EU markets (France, Germany, Italy, Spain, and th....
|2||Jun, 2020||Eliquis Drug Sales & Forecast|
BMS drug Eliquis (apixaban) is an oral Factor Xa inhibitor, targeted at stroke prevention in adult patients with NVAF and the prevention and treatment of ....
|3||Jun, 2020||Empliciti Drug Sales & Forecast|
BMS and AbbVie jointly develop and commercialize Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma. Both parties participat....
|4||Jun, 2020||Opdivo/Yervoy Drug Sales & Forecast|
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the bodyâ€™s own immune system to help restore anti....
|5||Jun, 2020||Orencia Drug Sales & Forecast|
BMS drug Orencia (abatacept), a biological product, is a fusion protein indicated for adult patients with moderately to severely active rheumatoid arthrit....
|6||Jun, 2020||Sprycel Drug Sales & Forecast|
BMS drug Sprycel (dasatinib) is an oral inhibitor of multiple tyrosine kinase indicated for the first-line treatment of patients with Philadelphia chromos....